In Reply We thank the authors of the 2 letters responding to our randomized clinical trial (RCT) comparing mycophenolate mofetil (MMF) and rituximab in the treatment of steroid-dependent nephrotic syndrome (SDNS).1 They provide us the opportunity to further discuss the main finding of our study, specifically the minimum effective dose of MMF in the treatment of complicated nephrotic syndrome. Schreuder et al and Belluzzi et al raised an important point, contesting that previous studies had already established the appropriate dosage of MMF for SDNS.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Angeletti A, Ravani P, Ghiggeri GM. Inadequate Dosage of Mycophenolate Mofetil Is Likely to Yield Substandard Trial Results and Substandard Patient Care—Reply. JAMA Pediatr. 2021;175(8):870–871. doi:10.1001/jamapediatrics.2021.1068
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.